Novavax Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Novavax (NVAX) Tops Q3 EPS by 2c; Will Implement Restructuring Plan
November 9, 2016 4:07 PM ESTNovavax (NASDAQ: NVAX) reported Q3 EPS of ($0.24), $0.02 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $4.02 million.
The Company presented a restructuring plan designed to meet the following key objectives:
Prioritize development activities to achieve clinical data events within 2017;Reduce cash burn, extend financial horizon and minimize near-term dilution; andMaintain operational core competencies to execute development plans.The... More
